首个“中国籍”地舒单抗在美获批上市!复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场

智通财经
Sep 02, 2025
【首个“中国籍”地舒单抗在美获批上市!复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场】智通财经APP讯,9月2日,复宏汉霖(02696.HK)与Organon(OGN)今日共同宣布,美国食品药品监督管理局(FDA)已批准地舒单抗注射液(60mg/mL)BILDYOS®(denosumab-nxxp)和地舒单抗注射液(120mg/1.7mL)BILPREVDA®(denosumab-nxxp)的上市申请。两款产品分别为PROLIA®(denosumab)和XGEVA®(denosumab)的生物类似药,此次获批复盖原研产品在美国已获批的所有适应症。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10